ReviewEJNMMI research2021
Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.
Review in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?Contrast media & molecular imaging · 2022Pooled it
- State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [International journal of molecular sciences · 2021Pooled it
- Fibroblast activation protein-targeted PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2025Trial
- The role of [European journal of nuclear medicine and molecular imaging · 2023Trial
- [⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study.European journal of nuclear medicine and molecular imaging · 2026Article
- Gastrointestinal cancer with indeterminateOncology letters · 2026Article
- Automated and manual synthesis of [EJNMMI radiopharmacy and chemistry · 2026Article
- Article
- [RMD open · 2026Article
- Ga-68 FAPI-04 PET/CT detection of repeatedly biopsy-negative poorly differentiated gastric adenocarcinoma: a case report.Frontiers in medicine · 2026Article
- Fibroblast activation protein inhibitor radiotheranostics for imaging activated tumor stroma and guiding radionuclide therapy.Frontiers in oncology · 2026Review
- SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Cryo-electron microscopy reveals a single domain antibody with a unique binding epitope on fibroblast activation protein alpha.bioRxiv : the preprint server for biology · 2024Article
- Progressive changes in the protein expression profile of alveolar septa in early-stage lung adenocarcinoma.International journal of clinical oncology · 2024Article
- The comparative utility of FAPI-based PET radiotracers over [American journal of nuclear medicine and molecular imaging · 2024Review
- IncreasedSkeletal radiology · 2023Article
- Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease.Frontiers in nuclear medicine · 2023Review
- PET Tracers for Imaging Cardiac Function in Cardio-oncology.Current cardiology reports · 2022Review
- The potential utility of [European journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSmall molecules targeting fibroblast activation protein (FAP) have emerged as a new group of tracers for positron emission tomography (PET) in 2018. While most of the existing literature has been focussed on the application of FAP-specific PET in various kinds of cancers, some researchers have, both intentionally or unintentionally, used FAP-specific PET in patients with non-cancerous diseases. The purpose of this systematic review is therefore to summarize the available evidence of FAP-specific PET for non-malignant indications.
methodsThe MEDLINE database was searched for studies presenting the clinical use of FAP-specific PET, the records were screened according to PRISMA guidelines and articles containing patients suffering from non-malignant diseases were included.
resultsSixteen studies with 303 patients were included. FAP-specific PET has been used in cardiac imaging, IgG
conclusionWhile publications on FAP-specific PET for non-malignant indications are mostly limited to case reports and incidental findings, the first retrospective and prospective studies present promising results for IgG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.